Cargando…

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

SIMPLE SUMMARY: To ameliorate the situation for kidney cancer patients and to broaden the application of available drugs, we initiated this research to enhance the anti-cancer activity through combination treatment. There is an unmet need for innovative treatment strategies and optimized drug combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rausch, Magdalena, Weiss, Andrea, Zoetemelk, Marloes, Piersma, Sander R., Jimenez, Connie R., van Beijnum, Judy R., Nowak-Sliwinska, Patrycja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693411/ https://www.ncbi.nlm.nih.gov/pubmed/33126775 http://dx.doi.org/10.3390/cancers12113172

Ejemplares similares

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
por: Zoetemelk, Marloes, et al.
Publicado: (2019)

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
por: van Beijnum, Judy R., et al.
Publicado: (2020)

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2020)

Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
por: Hany, Dina, et al.
Publicado: (2023)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
por: Weiss, Andrea, et al.
Publicado: (2019)

Erratum: Berndsen, R.H., et al. Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib, Cancers 2019, 11, 1878
por: Berndsen, Robert H., et al.
Publicado: (2020)

Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
por: Berndsen, Robert H., et al.
Publicado: (2019)

Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression
por: Berndsen, Robert H., et al.
Publicado: (2019)

Erratum to: miRNAs: micro-managers of anticancer combination therapies
por: van Beijnum, Judy R., et al.
Publicado: (2017)

miRNAs: micro-managers of anticancer combination therapies
por: van Beijnum, Judy R., et al.
Publicado: (2017)

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2021)

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization
por: Weiss, Andrea, et al.
Publicado: (2014)

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition
por: Nowak-Sliwinska, P, et al.
Publicado: (2015)

A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7)
por: van Beijnum, Judy R., et al.
Publicado: (2017)

Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2010)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2012)

Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells
por: Gnedina, Olga O., et al.
Publicado: (2023)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2018)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
por: Zhang, He, et al.
Publicado: (2020)

Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy
por: van Beijnum, Judy R., et al.
Publicado: (2022)

CLU blocks HDACI-mediated killing of neuroblastoma
por: Subramanian, Chitra, et al.
Publicado: (2010)

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Re-assessment of the high-grade serous ovarian cancer phosphoproteome – Identification of kinase candidates in TCGA tumors for future clinical intervention
por: Rolfs, Frank, et al.
Publicado: (2019)

Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets
por: Rausch, Magdalena, et al.
Publicado: (2021)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

Vimentin, colon cancer progression and resistance to butyrate and other HDACis
por: Lazarova, Darina L., et al.
Publicado: (2016)

The Promising Role of New Generation HDACis in Anti-Cancer Therapies
por: Hervouet, Eric
Publicado: (2018)

Teratoma Growth Retardation by HDACi Treatment of the Tumor Embryonal Source
por: Krasic, Jure, et al.
Publicado: (2020)

HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
por: Squarzoni, Angelica, et al.
Publicado: (2022)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kq38pvojshpsst2r6c37v19ceu